Daniel Lynch
CIK 1177082 · Chairman · last filed 2025-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SWTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 0 | $46.99 | $0 | -$12.42M | 11 | 2025-07-02 |
| 2seventy bio, Inc. (TSVT) Delisted | Director | 21,053 | $5.00 | $105.3K | $0 | 3 | 2023-06-15 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 398 | $4.97 | $2.0K | -$8.17M | 27 | 2021-11-17 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 127,904 | $129.46 | $16.56M | -$5.84M | 18 | 2020-06-26 |
| Translate Bio, Inc. (TBIO) Delisted | Director | — | $0.00 | — | $0 | 2 | 2020-06-17 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 2 | 2020-06-12 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | 161,430 | — | — | $0 | 4 | 2017-05-23 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 4 | 2016-06-22 |
Recent Filings · Page 8 of 8
76 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-18 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-10 | DNIB UNWIND, INC. (BIND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-08 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-13 | DNIB UNWIND, INC. (BIND) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-13 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | +70,879 | $0 | EDGAR |
| 2013-09-27 | DNIB UNWIND, INC. (BIND) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.